 |
 |
 |
 |
 |
 |
 |
|
 |
 |
Press ReleasesGenstruct Appoints William M. Ladd, Ph.D., Vice President of Discovery SystemsCambridge, Mass. — April 15, 2004 — Genstruct Inc., a biotechnology company that develops computable biological models to determine compound mechanisms of action and identify biomarkers for drug discovery and development, today announced the appointment of William M. Ladd, Ph.D. as Vice President - Discovery Systems. Dr. Ladd will lead development of the company's Molecular EpistemicsTM Platform and Global Knowledge Repository. William M. Ladd has over 18 years experience in the pharmaceutical and biotechnology industries, most recently leading Analytic and Life Science Product Strategy as Senior Director of Analytic Applications at Spotfire. Prior to Spotfire, Dr. Ladd was the Director of Bioinformatics Methods at Gene Logic and led the statistical analysis efforts of the Biological Data department at Merck. "I am delighted to be working with Bill again. His vision and leadership were vital to successful technology development at several leading biotechnology, pharmaceutical and software development companies - ideal experience to lead our Discovery Systems team" said Keith O. Elliston, Ph.D., President and CEO of Genstruct. "Bill will contribute unique experience and expertise that are critical for our technology platform development and that will, I believe, enable Genstruct to reach its commercialization goals more quickly and effectively." Genstruct deploys its Molecular Epistemics discovery platform independently and in partnerships with pharmaceutical companies to streamline drug discovery and improve clinical trial design and implementation. The platform is designed to build logical models of biological systems that uncover and define compound mechanisms of action and disease mechanisms. To date, Genstruct has focused primarily on the disease areas of oncology, metabolic disorders, and inflammation. The company believes that the identification of mechanisms and biomarkers in these areas will ultimately lead to better target choices, optimal clinical trial design and execution, and faster FDA product approval. About Genstruct Genstruct, founded in 2001, has developed a platform for the discovery of compound mechanism of action (MOA) and biomarkers called Molecular EpistemicsTM . The platform comprises a suite of patent pending technologies that model and analyze compound MOA: the Knowledge AssemblyTM process which enables rapid, ongoing construction of an addressable biological knowledgebase; and a set of tools for mining and refining the knowledgebase including the Epistemics EngineTM process for pathway discovery and validation. Genstruct is developing discovery and development partnerships that apply the Molecular EpistemicsTM platform to accelerate and increase the output of drug discovery and development programs. The Company was co-founded by Flagship Ventures, based in Cambridge, MA. For more information please visit www.genstruct.com. Contact: Karen Higgins A & E Communications for Genstruct (610) 831-5723 khiggins@aandecomm.com Return to Press Releases |
 |
|
 |
| One Alewife Center | Cambridge, MA 02140 | (617) 547-5421 | sitemap |